Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and torsade de pointes

Internal Medicine

Volumn 48, Issue 14, 2009, Pages 1219-1223

  Tanaka, Atsushi ^a   Koga, Shoichi ^a   Hiramatsu, Yoshihiro ^a  

^a Koga Hospital 21   (Japan)

Author keywords

Acetylcholinesterase inhibitors (AChIs); Atrioventricular block; Donepezil; QT prolongation; Torsade de pointes

Indexed keywords

AMLODIPINE; CILOSTAZOL; DONEPEZIL; ORCIPRENALINE; SPIRONOLACTONE; WARFARIN;

ADAMS STOKES ATTACK; AGED; ALZHEIMER DISEASE; ARTICLE; BACKACHE; BRADYCARDIA; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART VENTRICLE FIBRILLATION; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; MALE; NAUSEA; QT PROLONGATION; SINUS RHYTHM; SYNCOPE; THORAX RADIOGRAPHY; TORSADE DES POINTES; TRANSTHORACIC ECHOCARDIOGRAPHY; VERTEBRA FRACTURE; VOMITING;

AGED, 80 AND OVER; ATRIOVENTRICULAR BLOCK; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; PIPERIDINES; TORSADES DE POINTES;

EID: 70349538627     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2181     Document Type: Article

References (24)

1. Fragtiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in Elderly Research Group. Neurology 54: S10-S15, 2000.
2. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 120: 388-397, 2007.
3. Rowland JP, Rigby J, Harper AC, Rowland R. Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psych Treat 13: 178-184, 2007.
4. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Datebase Syst Rev CD 001747, 2006.
5. Coyle JT, Price DL, Delong MR. Alzheimer's disease; A disorders of cortical cholinergic innervation. Science 219: 1184-1190, 1983.
6. Calvo-Romero JM, Raomos-Sadlado JL. Symptomatic sinus bradycardia associated with donepezil. Rev Neurol 28: 1070-1072, 1999.
7. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 157: 4-15, 2000.
8. Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 42: 558-568, 2002.
9. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 33: 812-815, 1999.
10. Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation 64: 1167-1174, 1981.
11. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 89: 1363-1372, 2003.
12. Bordier P, Lanusse S, Garrigue S, et al. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging 22: 687-694, 2005.
13. Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother 42: 278-283, 2008.
14. Zareba W. Drug induced QT prolongation. Cardiol J 14: 523-533, 2007.
15. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104: 569-580, 2001.
16. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 229-307, 1995.
17. De Bruin ML, Pettersson M, Meyboom RH, et al. Anti-HERG activity and risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590-597, 2005.
18. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 24: 323-351, 2001.
19. Gladman G, Davis AM, Fogelman R, et al. Torsade de pointes, acquired complete heart block and inappropriately long QT in childhood. Can J Cardiol 12: 683-685, 1996.
20. Kurita T, Ohe T, Marui N, et al. Bradycardia-induced abnormal QT prolongation on patients with complete atrioventricular block with torsade de pointes. Am J Cardiol 69: 528-633, 1992.
21. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2: S9-S15, 2005.
22. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 17: 43-51, 2002.
23. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsade de pointes. Circulaton 105: 1943-1948, 2002.
24. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 106: 1269-1274, 2002.